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Abstract
Background—Symptom-based screening for tuberculosis (TB) is recommended for all people 
living with HIV (PLHIV) resulting in unnecessary Xpert MTB/RIF testing for the vast majority of 
individuals living in TB endemic areas and thus, poor implementation of intensified case finding 
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(ICF) and TB preventive therapy. Novel approaches to TB screening are therefore critical in 
achieving global targets for TB elimination.
Methods—In a prospective study of PLHIV with CD4+ T-cell count ≤350 cells/uL initiating 
antiretroviral therapy (ART) from two HIV/AIDS clinics in Uganda, we evaluated the performance 
of C-reactive protein (CRP) measured using a rapid and inexpensive point-of-care (POC) assay as 
a screening tool for active pulmonary TB.
Findings—Of 1177 HIV-infected adults (median CD4+ T-cell count 168 cells/µL) enrolled, 163 
(14%) had culture-confirmed TB. POC CRP had 89% (145/163) sensitivity and 72% (731/1014) 
specificity for culture-confirmed TB. Compared to the WHO symptom screen, POC CRP had 
lower sensitivity (difference −7% [95% CI: −12 to −2], p=0.002) but substantially higher 
specificity (difference +58% [95% CI: +61 to +55], p<0.0001). When Xpert MTB/RIF results 
were used as the reference standard, sensitivity of POC CRP and the WHO symptom screen were 
similar (94% [79/84] vs. 99% [83/84]; difference −5% [95% CI: −12 to +2], p=0.10).
Interpretation—The performance characteristics of CRP support its use as a TB screening test 
for PLHIV with CD4+ T-cell count ≤350 cells/µL initiating ART. HIV/AIDS programs should 
consider POC CRP-based TB screening to improve the efficiency of ICF and increase uptake of 
TB preventive therapy.
FUNDING—National Institutes of Health; Presidential Emergency Plan for AIDS Relief; 
University of California, San Francisco, Nina Ireland Program for Lung Health
INTRODUCTION
Since 2000, global tuberculosis (TB) incidence has fallen by an average of 1·5% annually.1 
Yet TB remains the leading infectious cause of death, responsible for 1·5 million deaths 
overall and 400,000 HIV-deaths (one-third of all HIV-deaths) in 2015 alone.1 To reduce the 
burden of TB, the World Health Organization (WHO) recommends systematic TB screening 
of all PLHIV, regardless of symptoms.2
The goals of screening are to: 1) detect active TB early to reduce the risk of poor disease 
outcomes and TB transmission and 2) identify individuals eligible for preventive therapy to 
reduce incident TB.2 A major barrier to implementing systematic screening of high-risk 
groups is the lack of an adequate TB screening test. The WHO target product profile for a 
TB screening test requires that sensitivity be ≥90% and specificity ≥70%.3 The high 
sensitivity requirement ensures that individuals who screen-negative have a low probability 
of active TB and can therefore initiate preventive therapy safely. The moderately high 
specificity requirement limits the need for confirmatory diagnostic testing to a smaller sub-
group of high-risk individuals. In addition to these technical requirements, the test should be 
simple, low-cost, and available at the point-of-care (POC) such that TB screening could be 
performed by frontline healthcare workers.
For PLHIV, no current test or algorithm satisfies the minimum criteria for a TB screening 
test. Although simple and highly sensitive (>90%) for active TB, the WHO-recommended 
symptom screen has insufficient specificity.4,5 Prospective studies from sub-Saharan Africa 
have shown that the specificity of the symptom screen is low (range: 5–33%).6–10 If 
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performed routinely, symptom-based TB screening would require nearly all PLHIV to 
undergo confirmatory testing11 before initiating life-saving TB preventive therapy. 
Therefore, to facilitate implementation of ICF and preventive therapy, there is an urgent need 
for a screening strategy that has higher specificity for active TB than the WHO symptom 
screen but retains high negative predictive value (NPV) and can be used at peripheral health 
centers in resource-limited settings.
C-reactive protein (CRP) is an acute-phase reactant whose concentrations rise in response to 
inflammation induced by diseases such as active TB.12–19 CRP has been consistently shown 
to have higher sensitivity for pulmonary TB compared to other non-specific markers of 
inflammation such as erythrocyte sedimentation rate, lactate dehydrogenase, and 
procalcitonin.12–14,20–23 Although elevations in CRP (≥10 mg/L) are not specific for active 
TB, two studies that evaluated CRP as a screening test among PLHIV initiating antiretroviral 
therapy (ART) found CRP, using stored serum specimens, to have two- to six-fold higher 
specificity (58% and 81%) than symptom-based TB screening.18,19 These studies suggest 
that CRP – which is already available as a simple, rapid, and low-cost POC test (results in 3 
minutes, <$2 per test) – may be a promising approach to TB screening.
We report on the first prospective study of POC CRP-based TB screening for PLHIV 
presenting to prototypical HIV/AIDS clinics for ART initiation. Our objectives were to 
determine whether POC CRP meets the minimum sensitivity and specificity targets 
recommended by the WHO for TB screening, thereby assessing whether POC CRP might 
improve the effectiveness and efficiency of screening relative to the WHO-recommended 
symptom screen.
METHODS
Study population
From July 2013 to December 2015, we enrolled consecutive adults (age ≥18 years) initiating 
ART from two HIV/AIDS clinics within the Mulago Hospital Complex (Kampala, Uganda). 
Patients were included if they were ART-naïve and had a pre-ART CD4+ T-cell count ≤350 
cells/µL within three months of study enrollment. Patients with a known diagnosis of active 
TB and/or taking medication with anti-mycobacterial activity (anti-TB or TB preventive 
therapy, fluoroquinolones) within three days of enrollment were excluded. All patients 
provided written informed consent and the study was approved by the Institutional Review 
Boards at the University of California, San Francisco, Makerere University, and the Uganda 
National Council for Science and Technology. This study conforms to the Standards for the 
Reporting of Diagnostic Accuracy Studies (STARD) initiative guidelines.24
Study procedures
Data collection and TB screening—Trained study personnel collected demographic 
and clinical data and administered the WHO symptom screen at the time of enrollment. CRP 
concentrations were measured at study entry using whole blood obtained from finger prick 
using a United States Food and Drug Administration (US FDA)-approved standard 
sensitivity POC assay (iCHROMA, BodiTech, South Korea).
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Sputum collection and testing—Two spot sputum samples (the second induced using 
nebulized 3% hypertonic saline, if necessary) were collected at study entry. A minimum of 
one mL of sputum from the first sputum specimen was processed for Xpert MTB/RIF 
(Xpert) testing (Cepheid, USA). The remaining volume from the first sputum specimen and 
the second sputum specimen underwent decontamination with N-acetyl-L-cysteine and 
sodium hydroxide. Mycobacterial culture was performed on the decontaminated sediments; 
sediments were cultured on liquid media using the BACTEC 960 Mycobacterial Growth 
Indicator Tube (MGIT) system, with parallel solid (Löwenstein-Jensen) media added from 
June 2014 to December 2015. Laboratory technicians confirmed the identity of any growth 
by acid-fast bacilli smear microscopy and molecular speciation testing (Capilia TB, TAUNS, 
Japan or MPT64 assay, Standard Diagnostics, South Korea). All staff performing Xpert 
testing and culture were blinded to clinical and demographic data, including symptom screen 
status and POC CRP concentrations.
Definitions
Index tests—We defined a priori a POC CRP concentration of ≥10 mg/L (rounding to the 
nearest whole-number) as screen-positive for TB based on large-scale epidemiological 
studies of other conditions.25,26 In accordance with WHO guidelines, we considered patients 
to be symptom screen-positive if they reported any of four symptoms (current cough, fever, 
night sweats, weight loss) in the previous 30 days.2
Reference standard—We considered patients to have active TB if Mycobacterium 
tuberculosis (Mtb) was isolated from any sputum culture. We considered patients not to have 
active TB if: 1) Mtb was not isolated from any sputum culture, and 2) at least two sputum 
cultures were negative. Patients with insufficient culture data (e.g., due to contamination) 
were excluded from analysis. Secondarily, to evaluate CRP performance in the context of 
routine ICF, we also classified TB status based on Xpert results.
Statistical analysis
Comparisons between groups of categorical and continuous variables were performed using 
the Wilcoxon rank-sum test, t-test, or chi-square test as appropriate. For the primary 
analysis, we calculated the point estimates and 95% confidence intervals (CIs) for the 
sensitivity, specificity, NPV, and positive predictive value (PPV) of POC CRP and the WHO 
symptom screen in reference to culture results. We compared differences in sensitivity and 
specificity between the WHO symptom screen and POC CRP using McNemar’s test of 
paired proportions. To identify the optimal cut-point for POC CRP-based TB screening, we 
performed receiver operating characteristic (ROC) analysis to explore the sensitivity, 
specificity, and predictive values of alternate thresholds. To explore the prognostic value of 
POC CRP concentrations with mycobacterial load, we calculated the Pearson’s correlation 
coefficient between POC CRP concentrations and days-to-culture positivity. We performed 
all analyses using STATA 13 (STATA, USA).27
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Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
RESULTS
Study population
During the study period, 1246 consecutive PLHIV were screened and 1237 eligible 
participants were enrolled and underwent POC CRP testing. Sixty patients (5%) with 
incomplete and/or contaminated cultures were excluded from the analysis (Figure 1). Of the 
remaining 1177 patients, 626 were female (53%), median age was 33 years (interquartile 
range [IQR] = 27–40), and median CD4+ T-cell count was 165 cells/µL (IQR 75–271; Table 
1). Overall, 163 patients (14%) had culture-confirmed TB, with TB prevalence increasing as 
CD4+ T-cell count decreased (p<0·001 for trend). TB prevalence was 7% (33/486), 15% 
(48/311), 19% (32/169), and 24% (50/2011) among patients with CD4+ T-cell counts >200, 
100–200, 50–99, and <50 cells/µL, respectively. Xpert was positive in 84/163 patients 
(sensitivity 52%, 95% CI: 44 to 59) with culture-confirmed TB and 8/1014 patients 
(specificity 99%, 95% CI: 99 to 100) with negative cultures.
POC CRP test characteristics
Sensitivity—POC CRP concentrations were elevated (≥10 mg/L) in 428/1177 (36%) 
patients, including 145/163 patients with culture-confirmed TB (sensitivity 89%, 95% CI: 83 
to 93; Table 2) and 79/84 patients with Xpert-positive TB (sensitivity 94%, 95% CI: 87 to 
98). Among patients with CD4+ T-cell counts ≤200 cells/µL, sensitivity for culture-
confirmed TB was 93% ([121/130], 95% CI: 87 to 97; Appendix, page 1) and did not vary 
by CD4+ strata within this group (p=0·65 for trend; Figure 2A) but was lower (73% [24/33], 
95% CI: 55 to 87) for patients with CD4+ T-cell counts >200 cells/µL. NPV was high 
overall (98%, 95% CI: 96 to 99) and for all CD4+ strata (range: 96 to 100%).
Specificity—POC CRP concentrations were not elevated (<10 mg/L) in 731/1014 patients 
without TB (specificity 72%, 95% CI: 69 to 75; Table 2). Among patients with CD4+ T-cell 
counts ≤200 cells/µL, specificity was 66% ([367/561], 95% CI: 61 to 69; Appendix, page 1) 
and was similar (range 62–67%) for all CD4+ strata within this group (p=0·73 for trend; 
Figure 2B). Specificity was higher (80% [364/453], 95% CI: 76 to 84) among patients with 
CD4+ T-cell counts >200 cells/µL.
Correlations with measures of mycobacterial load—Median POC CRP 
concentrations were higher in patients with culture-confirmed TB compared to those with 
negative cultures (51·3 mg/L [IQR 21·9–112·8] vs. 3·4 mg/L [IQR 2·5–11·6], p<0·0001), and 
higher in patients with Xpert-positive TB compared to those with Xpert-negative TB (67·1 
mg/L [IQR 30·7–141·2] vs. 36·9 mg/L [IQR 13·1–88·7], p=0·003). POC CRP concentrations 
increased as days-to-culture positivity decreased, though correlation was modest (r = −0·28, 
p=0·0003; Appendix, page 2).
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Comparison with the WHO symptom screen
In contrast to POC CRP, the majority of patients (87%, 1025/1177) screened positive by 
symptoms (difference +51%, 95% CI: +48 to +54). Compared to POC CRP, the WHO 
symptom screen had higher sensitivity (89% [145/163] vs. 96% [156/163]; difference +7% 
[95% CI: +2 to +12], p=0·002; Table 2) but substantially lower specificity (72% [731/1014] 
vs. 14% [145/1014]; difference −58% [95% CI: −61 to −55], p<0·0001). When Xpert was 
used as the reference standard, sensitivity of POC CRP and the WHO were similar (94% 
[79/84] vs. 99% [83/84]; difference +5% [95% CI: −2 to +12], p=0·10; Appendix, page 1). 
For all CD4+ strata, specificity of the WHO symptom screen (range: 4–19%) was 
substantially lower than the specificity of POC CRP (range 62–80%; Appendix, page 1).
Diagnostic accuracy of combined TB screening strategies
Supplementary Table 3 (Appendix, page 3) shows the diagnostic accuracy of two 
combination TB screening strategies (any test positive and both test positive) in reference to 
culture. Neither combination approach to TB screening improved the diagnostic accuracy 
beyond that of an individual screening test.
ROC analysis
Figure 3 shows the ROC curve for POC CRP. POC CRP met the minimum TB screening test 
sensitivity (≥90%) and specificity (≥70%) targets when the cut-point was lowered to 8 mg/L 
(AUROC 0·80, 95% CI: 0·77 to 0·83) or 9 mg/L (AUROC 0·81, 95% CI: 0·78 to 0·83; Table 
3).
DISCUSSION
In this study, we screened 1177 HIV-infected adults with CD4+ T-cell counts ≤350 cells/µL 
initiating ART for active TB with a rapid and inexpensive POC CRP assay using whole 
blood obtained from finger prick. POC CRP-based TB screening detected 89% of all 
culture-confirmed and 94% of all Xpert-positive TB cases. Furthermore, POC CRP correctly 
identified 72% of all PLHIV without active TB as immediately eligible for preventive 
therapy. These results identify POC CRP as the first test to meet the minimum accuracy 
criteria established by the WHO for a TB screening tool among PLHIV, a key high-risk 
population targeted for systematic screening.
Our findings are consistent with multiple prior studies that have found elevated CRP 
concentrations to strongly predict the presence of active TB among PLHIV.12–19 Studies 
evaluating CRP among patients self-reporting TB symptoms (i.e., passive case detection) 
have consistently found CRP to have high sensitivity (range: 89–100%) for active TB.12–17 
However, because patients self-reporting symptoms have a higher prevalence of pyogenic 
infections (e.g., bacterial pneumonia), specificity of CRP has been generally low (range: 0–
43%) in this population.13–15,17 Recently, two studies used stored serum specimens to 
evaluate CRP in the context of TB screening among PLHIV (i.e., active case detection).18,19 
CRP had similar sensitivity but two- to six-fold higher specificity for active TB, relative to 
the WHO symptom screen.18,19 Our findings from the first prospective evaluation of POC 
CRP as a TB screening tool validate these prior analyses, and strongly support that POC 
Yoon et al. Page 6
Lancet Infect Dis. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CRP-based TB screening could improve the efficiency of ICF and increase the uptake of TB 
preventive therapy.
Despite WHO recommendations, only 7 million PLHIV were screened for TB and <1 
million were provided TB preventive therapy worldwide in 2014.28 The high false-positive 
rate of the WHO symptom screen, the currently recommended screening test for PLHIV, has 
hampered efforts to scale-up both ICF and preventive therapy. Consistent with prior 
prospective studies,6–10 our data found that 86% of PLHIV without active TB screened 
false-positive by symptoms. Although the WHO symptom screen exceeded the minimum 
sensitivity threshold (≥90%) for a TB screening test, the poor specificity (14%) of the WHO 
symptom screen precludes its usefulness in this population.
For a TB screening test to be considered by policymakers and clinicians alike, the test must 
prioritize sensitivity over specificity. The extent to which sensitivity of a TB screening test 
should be prioritized over specificity is described by the WHO’s target product profile for a 
TB screening test, which recommends ≥90% sensitivity and ≥70% specificity.3 This trade-
off between sensitivity and specificity takes into consideration the risks associated with a 
patient who screens false-negative (e.g., generation of isoniazid-resistant TB) and the burden 
patients who screen false-positive would have on the healthcare system (e.g., costs and 
workload of unnecessary confirmatory testing). Our data suggests that if culture is used as 
the confirmatory TB test, the WHO symptom screen would detect 7% more TB cases than 
POC CRP but would require nearly all (87%) patients to undergo culture, which is likely to 
be cost-prohibitive even in the few high burden countries where culture is more readily 
available. In contrast, POC CRP would detect 89% of all culture-confirmed TB cases but 
would require only 36% of all patients to undergo culture, an absolute reduction of 51% 
relative to the WHO symptom screen. When either an 8 or 9 mg/L cut-point was used, POC 
CRP met both the minimum sensitivity (≥90%) and specificity (≥70%) thresholds 
recommended by the WHO target product profile for a TB screening test. Furthermore, POC 
CRP would perform particularly well among patients with low CD4+ T-cell counts. 
Additional studies are needed to confirm whether POC CRP-based TB screening using a 
cut-point of 8 or 9 mg/L would further improve the effectiveness of TB screening and formal 
cost-effectiveness studies are needed to better estimate the costs and yield of POC CRP-
based TB screening relative to current options.
In the vast majority of settings that use Xpert as the confirmatory test, our data show that 
POC CRP would detect 94% of all Xpert-positive patients but reduce by more than half 
(60% absolute reduction) the number of patients who would require Xpert testing relative to 
symptom-based screening. Therefore, POC CRP-based TB screening would identify nearly 
all Xpert-positive TB cases (cases that pose the greatest infectious risk to the community) 
but substantially lower the cost of ICF activities.
Our study has several strengths. First, our study findings are likely generalizable to a number 
of other HIV-endemic settings as our study participants represent a prototypical population 
for whom TB screening is recommended. Second, all patients, regardless of symptoms, were 
screened and then evaluated for TB using a robust standard for TB diagnosis: two MGIT 
cultures. Third, CRP concentrations were measured using a commercially available, simple 
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and low-cost POC assay. As such, POC CRP is available for immediate scale-up for HIV/
AIDS clinics wishing to implement POC CRP-based TB screening and further strengthen its 
evidence base. Future studies evaluating POC CRP-based TB screening should also evaluate 
whether the diagnostic accuracy of POC CRP-based TB screening may be further improved 
when used in combination with CXR and/or other promising biomarkers, particularly among 
patients with high CD4+ T-cell counts and/or patients treated with ART.
Our study also has limitations. First, we chose to study ART-naïve patients with advanced 
HIV-associated immunosuppression because TB risk is greatest in this population. Our study 
findings may therefore be less applicable to other HIV sub-groups. Future studies should 
evaluate the diagnostic accuracy of POC CRP in ART-treated PLHIV, other high-risk 
populations (e.g., household contacts, miners, prisoners, etc.) for whom systematic TB 
screening is also recommended, and other high burden settings.52 Second, we classified TB 
status based on culture results, the gold standard for TB diagnosis. Although TB 
classification based on clinical criteria may have resulted in additional TB cases identified 
for our analysis, empiric TB treatment was uncommon in our TB screening cohort (i.e., 
PLHIV undergoing active case finding rather than PLHIV seeking care for symptoms 
suggestive of TB). Third, we did not compare CRP concentrations measured using a POC 
assay in our study to a lab-based assay as prior studies including a US FDA-led 
investigation, have demonstrated excellent correlation of the iCHROMA POC CRP assay 
with the reference standard, and minimal variation with repeated testing of the same sample 
over a large range of CRP concentrations.29 Lastly, we did not evaluate patients for extra-
pulmonary TB or for non-TB disease. Future studies should evaluate the diagnostic accuracy 
of POC CRP for extra-pulmonary TB and assess the causes and significance of an elevated 
POC CRP level among PLHIV with non-TB disease.
In conclusion, our findings have important implications for clinical care and program 
implementation. POC CRP-based TB screening could substantially increase the number of 
PLHIV initiating ART identified as eligible for TB preventive therapy and reduce the 
number of PLHIV requiring confirmatory TB testing. Thus, POC CRP could increase uptake 
of TB preventive therapy and decrease costs of implementing ICF beyond that of symptom-
based screening. These results support the use of POC CRP as a part of a public health 
strategy to reduce the global burden of TB among PLHIV.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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RESEARCH IN CONTEXT
Evidence before this study
C-reactive protein (CRP) is an acute-phase reactant whose levels rise in response to 
pyogenic infections such as active pulmonary tuberculosis (TB) and is independent of 
HIV status. Although elevations in CRP (≥10 mg/L) are not specific for active TB, CRP 
has been consistently shown to have higher sensitivity for active TB compared to other 
inflammatory markers. Moreover, CRP can be measured using low-cost and simple point-
of-care (POC) assays from blood obtained by finger prick. To identify all studies that 
measured blood CRP levels from consecutive patients undergoing screening or evaluation 
for active pulmonary TB, we performed a systematic review of PubMed with the search 
terms “C-reactive protein” and “tuberculosis” for English-language studies published on 
or before June, 2017. We found that most studies evaluated the diagnostic accuracy of 
CRP for active TB in the setting of passive case finding (i.e., diagnosis-seeking patients 
with symptoms suggestive of TB). In these studies, CRP had high sensitivity but low 
specificity for active TB. We found two studies that evaluated the diagnostic accuracy of 
CRP for active TB in the setting of active case finding (i.e., provider-initiated screening). 
Using stored specimens of HIV-infected patients initiating antiretroviral therapy (ART), 
both studies found that CRP had comparably high sensitivity for active TB as symptom-
based screening (the current standard) but substantially higher specificity. However, no 
study has prospectively evaluated CRP as a TB screening tool for PLHIV and it is 
unknown whether CRP meets the World Health Organization’s (WHO) target product 
profile (sensitivity ≥90% and specificity ≥70%) for a TB screening test.
Added value of this study
Our study is the first to prospectively evaluate the diagnostic accuracy of CRP in the 
context of TB screening. We found that CRP, using a POC assay, had 89% sensitivity and 
72% specificity for culture-confirmed TB while symptom-based screening had higher 
sensitivity (96%) but substantially lower specificity (14%). When Xpert MTB/RIF – the 
confirmatory test most commonly used in resource-limited settings – was used as the 
reference standard, POC CRP detected 94% of all Xpert-positive TB cases. Thus, POC 
CRP is the first TB screening tool to meet the minimum accuracy targets established by 
the WHO.
Implications of all the available evidence
Previously published data and our results support the use of CRP to systematically screen 
PLHIV initiating ART for active TB. POC CRP-based TB screening could improve the 
efficiency of ICF and increase the uptake of TB preventive therapy among PLHIV. In 
order to support policy recommendations, studies and programs performing systematic 
TB screening among PLHIV should incorporate POC CRP into their TB screening 
protocols and evaluate costs and yield relative to current options.
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Figure 1. 
Patient flow diagram.
Abbreviation: ART (antiretroviral therapy); POC CRP (point-of-care C-reactive protein); 
TB (tuberculosis).
*All enrolled participants underwent POC CRP testing and submitted two spot specimens 
for liquid culture. TB defined as ≥1 sputum culture positive for Mycobacterium tuberculosis. 
No TB defined as ≥2 sputum cultures negative for Mycobacterium tuberculosis.
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Figure 2. 
A. Sensitivity of screening tests for culture-confirmed tuberculosis and Xpert-positive 
tuberculosis, stratified by CD4+ T-cell count.
Abbreviations: POC CRP (point-of-care C reactive protein); WHO (World Health 
Organization).
The dark blue bars represent the sensitivity of POC CRP while the light blue bars represent 
the sensitivity of the WHO symptom screen, in reference to culture (left) and Xpert (right).
In reference to culture: Among PLHIV with CD4+ T-cell counts <200 cells/uL, sensitivity 
of POC CRP for culture-confirmed TB did not vary significantly by CD4 strata (p = 0·65 for 
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trend). Compared to PLHIV with CD4+ T-cell counts ≥200 cells/uL, sensitivity of POC CRP 
was higher among PLHIV with CD4+ T-cell counts <200 cells/uL (73% vs. 93%; difference 
−20% [95% CI: −36 to −5], p-value for the difference =0·0002).
In reference to Xpert: Among PLHIV with CD4+ T-cell counts ≤350 cells/uL, sensitivity 
of POC CRP for Xpert-positive TB did not vary significantly by CD4 strata (p=0·56 for 
trend).
B. Specificity of screening tests for culture-positive tuberculosis, stratified by CD4+ T-cell 
count.
Abbreviations: POC CRP (point-of-care C reactive protein); WHO (World Health 
Organization).
The dark blue bars represent the specificity of POC CRP while the light blue bars represent 
the specificity of the WHO symptom screen, in reference to culture. Among PLHIV with 
CD4+ T-cell counts ≤350 cells/uL, specificity of the WHO symptom screen decreased 
significantly as CD4 strata decreased (p<0·0001 for trend). Among PLHIV with CD4+ T-
cell counts <200 cells/uL, specificity of POC CRP did not vary significantly by CD4 strata 
(p = 073 for trend). Compared to PLHIV with CD4+ T-cell counts ≥200 cells/uL, specificity 
of POC CRP was lower among PLHIV with CD4+ T-cell <200 cells/uL (80% vs. 66%; 
difference −14% [95% CI: −20 to −10], pvalue for the difference <0·0001).
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Figure 3. 
Receiver operating characteristic (ROC) curves for the detection of culture-confirmed 
pulmonary tuberculosis by POC CRP.
Abbreviations: POC CRP (point-of-care C-reactive protein).
Area under the receiver-operating curve for 10 mg/L (0·81, 95% CI: 0·78 to 0·83), 9 mg/L 
(0·81, 95% CI: 0·78 to 0·83), and 8 mg/L (0·80, 95% CI: 0·77 to 0·83) cut-points.
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Table 1
Demographics and clinical characteristics.
Characteristic, N (%) Median (IQR)/Number (%)
(Total N=1177)
Age (years) 33 (27–40)
Female 626 (53%)
New to HIV care 742 (63%)
CD4+ T-cell count (cells/µL) 165 (75–271)
    <50 211 (18%)
    50–99 169 (14%)
    100–199 311 (26%)
    ≥200 486 (41%)
BMI (kg/m2) 21·2 (18·9–24·0)
Prior TB 42 (4%)
TB contact 457 (39%)
WHO symptom screen 1025 (87%)
  Current cough 568 (48%)
  Fever 585 (50%)
  Night sweats 410 (35%)
  Weight loss 848 (72%)
Elevated POC CRP (≥10 mg/L) 428 (36%)
POC CRP (mg/L) 4·6 (2·5–24·5)
Abbreviations: IQR (interquartile range); BMI (body mass index); TB (tuberculosis); WHO (World Health Organization); POC CRP (point-of-
care C-reactive protein).
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Table 2
Diagnostic accuracy of POC CRP vs. WHO symptom screen for active tuberculosis (in reference to culture).
In reference to culture POC CRP WHO symptom
screen
% Difference
(95% CI)
p-value for
difference
TP/Culture-positive 145/163 156/163 −7%
0·002
% Sensitivity (95% CI) 89% (83–93) 96% (91–98) (−12 to −2)
TN/Culture-negative 731/1014 145/1014 +58%
<0·0001
% Specificity (95% CI) 72% (69–75) 14% (12–17) (+55 to +61)
TN/(TN+FN) 731/749 145/152 +2%
0·13
NPV (95% CI) 98% (96–99) 95% (91–98) (−1 to +6)
TP/(TP+FP) 145/428 156/1025 +19%
<0·0001
PPV (95% CI) 34% (29–39) 15% (13–18) (+14 to +24)
Abbreviations: POC CRP (point-of-care C-reactive protein); WHO (World Health Organization); CI (confidence interval); TP (true positive); TN 
(true negative); FN (false negative); FP (false positive); NPV (negative predictive value); PPV (positive predictive value).
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Table 3
Effect of varying POC CRP threshold on diagnostic accuracy.
POC CRP
cut-point (mg/L)
Sensitivity %
(95% CI)
Specificity %
(95% CI)
PPV %
(95% CI)
NPV %
(95% CI)
≥ 3 93·9% (89·0–97·0) 46·5% (43·4–49·7) 22·0% (19·0–25·3) 97·9% (96·2–99·0)
≥ 4 93·3% (88·2–96·6) 53·2% (50·0–56·3) 24·2% (20·9–27·8) 98·0% (96·4–99·0)
≥ 5 92·6% (87·5–96·1) 59·7% (56·6–62·7) 27·0% (23·3–30·8) 98·1% (96·6–99·0)
≥ 6 92·0% (86·7–95·7) 63·9% (60·9–66·9) 29·1% (25·2–33·2) 98·0% (96·7–98·9)
≥ 7 91·4% (86·0–95·2) 67·6% (64·6–70·4) 31·2% (27·0–35·5) 98·0% (96·7–98·9)
≥ 8 90·2% (84·5–94·3) 69·6% (66·7–72·4) 32·3% (28·0–36·8) 97·8% (96·4–98·7)
≥ 9 89·6% (83·8–93·8) 71·5% (68·6–74·3) 33·6% (29·1–38·2) 97·7% (96·4–98·7)
≥ 10 89·0% (83·1–93·3) 72·1% (69·2–74·8) 33·9% (29·4–38·6) 97·6% (96·2–98·6)
≥ 11 87·1% (81·0–91·8) 74·6% (71·8–77·2) 35·5% (30·8–40·4) 97·3% (95·9–98·3)
≥ 12 85·3% (78·9–90·3) 75·3% (72·6–78·0) 35·7% (31·0–40·7) 97·0% (95·5–98·0)
Abbreviations: POC CRP (point-of-care C-reactive protein); CI (confidence interval); PPV (positive predictive value); NPV (negative predictive 
value)·
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